

Background

Emerging evidence implicates the gut microbiome in the pathogenesis and progression of Parkinson's disease and related synucleinopathies. Notably, butyrate-producing bacteria are consistently reduced in these disorders. This study aimed to investigate the role of two key butyrate-producing commensals, *F. prausnitzii* and *B. faecis*, in synucleinopathy.

1. Study design





Figure 1. Male and female, α -synuclein 3KL and WT mice were gavaged live bacterial suspensions in culture media (including supernatant) of either *F. prausnitzii*, *B. faecis*, or OTEB broth twice per week for three months, from 6-9 months of age.

2. F. prausnitzii and B. faecis improve motor and cognitive phenotypes in male 3KL mice



3. F. prausnitzii and B. faecis alter microglial transcriptional profiles






Figure 3. *F. prausnitzii* and *B. faecis* alter microglial transcriptional profiles in male 3KL mice. Volcano plot of differentially expressed genes significantly altered by A) *F. prausnitzii* and B) *B. faecis* by bulk RNA sequencing of isolated microglia. Ingenuity Pathway Analysis revealed changes in canonical pathways including C) downregulation of inflammatory signaling pathways in response to *F. prausnitzii* and D) increased butyrate response genes and lipid metabolism in response to *B. faecis*. All pathways shown are statistically significant (P<0.05), two-sided Wald test using the DESeq2 package in R.

4. F. prausnitzii and B. faecis produce multiple SCFAs



5. F. prausnitzii and B. faecis alter host metabolomic profiles



Conclusions

These findings demonstrate that *F. prausnitzii* and *B. faecis* improve motor and cognitive function in a model of synucleinopathy through microglial and metabolic reprogramming. Distinct microbial metabolites, including betaine and unsaturated fatty acid-related compounds, were detected in recipient mouse brains, supporting a gut-brain mechanistic link. Together, these results highlight beneficial commensal microbes as modulators of neuroinflammation and metabolism and targeting the gut microbiome may represent a therapeutic strategy for synucleinopathies. This work is funded by the Susan and Charles Berghoff Foundation.